کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5536579 | 1402296 | 2017 | 7 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Identification and characterization of enhancer agonist human cytotoxic T-cell epitopes of the human papillomavirus type 16 (HPV16) E6/E7
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
adenovirus serotype 5PBMCMFICTLIn vitro stimulationORFHNSCCAd5APCGM-CSFHPV16IVSnatural killer - (سلول های) کشنده طبیعیCTLs - CTL هاMOI - MEHuman leukocyte antigen - آنتی ژن لوسکسی انسانantigen-presenting cell - آنتیژن ارائه سلولHLA - آنتیژن گلبول سفید انسانیPeripheral blood mononuclear cell - سلول تک هسته ای خون محیطیDendritic cell - سلول دندریتیکgranulocyte-macrophage colony-stimulating factor - عامل گرانولوسیت-ماکروفاژ colony-stimulating factoropen reading frame - قاب خواندن بازcytotoxic T lymphocyte - لنفوسیت T سیتوتوکسیکmajor histocompatibility complex - مجموعه سازگاری بافتی اصلیMHC - مجموعه سازگاری بافتی اصلیmean fluorescence intensity - میانگین شدت فلورسانسHuman papilloma virus - ویروس پاپیلومای انسانیHPV - ویروس پایپلوم انسانیmultiplicity of infection - چندین عفونتLate gene - ژن بعدEarly gene - ژن زودرسHead and neck squamous cell carcinoma - کارسینوم سلول سنگفرشی سر و گردن
موضوعات مرتبط
علوم زیستی و بیوفناوری
ایمنی شناسی و میکروب شناسی
ایمونولوژی
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
Human papillomavirus (HPV) is associated with the etiology of cervical carcinoma, head and neck squamous cell carcinoma, and several other cancer types. Vaccines directed against HPV virus-like particles and coat proteins have been extremely successful in the prevention of cervical cancer through the activation of host HPV-specific antibody responses; however, HPV-associated cancers remain a major public health problem. The development of a therapeutic vaccine will require the generation of T-cell responses directed against early HPV proteins (E6/E7) expressed in HPV-infected tumor cells. Clinical studies using various vaccine platforms have demonstrated that both HPV-specific human T cells can be generated and patient benefit can be achieved. However, no HPV therapeutic vaccine has been approved by the Food and Drug Administration to date. One method of enhancing the potential efficacy of a therapeutic vaccine is the generation of agonist epitopes. We report the first description of enhancer cytotoxic T lymphocyte agonist epitopes for HPV E6 and E7. While the in silico algorithm revealed six epitopes with potentially improved binding to human leukocyte antigen-A2 allele (HLA-A2)-Class I, 5/6 demonstrated enhanced binding to HLA-Class I in cell-based assays and only 3/6 had a greater ability to activate HPV-specific T cells which could lyse tumor cells expressing native HPV, compared to their native epitope counterparts. These agonist epitopes have potential for use in a range of HPV therapeutic vaccine platforms and for use in HPV-specific adoptive T- or natural killer-cell platforms.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Vaccine - Volume 35, Issue 19, 2 May 2017, Pages 2605-2611
Journal: Vaccine - Volume 35, Issue 19, 2 May 2017, Pages 2605-2611
نویسندگان
Kwong Y. Tsang, Massimo Fantini, Romaine I. Fernando, Claudia Palena, Justin M. David, James W. Hodge, Elizabeth S. Gabitzsch, Frank R. Jones, Jeffrey Schlom,